#ASH25: AstraZeneca’s dual-targeting CAR-T sees similar responses in Western patients as in Chinanews2025-12-06T20:00:15+00:00December 6th, 2025|Endpoints News|
Bristol Myers expands Breyanzi approval to marginal zone lymphomanews2025-12-05T19:17:02+00:00December 5th, 2025|Endpoints News|
Nationwide Children’s SLC6A1 gene therapy shows early promisenews2025-12-04T13:00:54+00:00December 4th, 2025|Endpoints News|
With Phase 3 Duchenne success, Capricor plots path forward after FDA rejectionnews2025-12-03T16:36:07+00:00December 3rd, 2025|Endpoints News|
China’s Zhongmou seeks to create a ‘one-size-fits-all’ rival to Luxturnanews2025-11-26T13:31:07+00:00November 26th, 2025|Endpoints News|
Aspen gets $115M for Parkinson’s cell therapy, potential IPO in sight next yearnews2025-11-20T12:02:48+00:00November 20th, 2025|Endpoints News|
Flagship’s Tessera to start first human trial using new gene writing platformnews2025-11-19T20:38:49+00:00November 19th, 2025|Endpoints News|
Protara trumpets small rare disease dataset in children for cell therapynews2025-11-19T15:57:02+00:00November 19th, 2025|Endpoints News|
Jeffrey Bluestone hands Sonoma CEO post to Stephen Dillynews2025-11-17T16:26:56+00:00November 17th, 2025|Endpoints News|
FDA updates Sarepta’s Duchenne gene therapy label, requests postmarketing studynews2025-11-14T20:48:04+00:00November 14th, 2025|Endpoints News|
